[ Sequentia ] Ac-D-2-Nal-D-4-Cl-Phe-D-3-Pal-Ser-N-Me-Tyr-D-Asn-Leu-Lys(ipr)-Pro-D-Ala-NH2
[ Synonyma ] PPI 149 acetate; Plenaxis;Abarelix
[ CAS NO. ] 183552-38-7
[ Formulae hypotheticae ] C74H99ClN14O16
[ M. Pondus ] 1476.138
[ Densitas ] 1.287 g/cm3
[ Ferveret ] 1688.37 °C at 760 mmHg
[ Mico punctum ] 974.891 °C
[ Aspectus ] Alba pulveris
[ Applicationem ] Active Pharmaceutical Ingredientia
[ Puritas ] 98%
[ Praecipua Function ]
Investigationes scientificae solum, nullum directum usum ad corpus humanum
Abarelix is a synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). in masculino, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.
Abarelix Acetate is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). Abarelix Acetate is primarily used in oncology to reduce the amount made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.
